A5048997104- Lung Cancer Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Frailty in Older Adults
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Head and Neck Cancer Studies
- Breast Cancer Treatment Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Nitric Oxide and Endothelin Effects
- Lymphoma Diagnosis and Treatment
- Brain Metastases and Treatment
- Cancer-related Molecular Pathways
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Cancer Genomics and Diagnostics
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Neuroinflammation and Neurodegeneration Mechanisms
- Complex Systems and Time Series Analysis
- Immune Cell Function and Interaction
- Protein Kinase Regulation and GTPase Signaling
- Histiocytic Disorders and Treatments
- PI3K/AKT/mTOR signaling in cancer
- Control and Stability of Dynamical Systems
- PARP inhibition in cancer therapy
- Immune cells in cancer
Kettering University
2024
Memorial Sloan Kettering Cancer Center
2023-2024
Johns Hopkins Medicine
2019-2020
Johns Hopkins University
2019-2020
University of Massachusetts Chan Medical School
2017-2020
UMass Memorial Medical Center
2017
Gilead Sciences (United States)
2016
Wake Forest University
2016
Baptist Health System
2013
Texas A&M University
2011
Abstract The KEYNOTE-522 (KN522) regimen for neoadjuvant treatment of triple negative breast cancer (TNBC) utilized q3week dosing doxorubicin plus cyclophosphamide (AC); however, dose-dense AC (ddAC) has demonstrated superior overall survival (OS) compared to in anthracycline and taxane-based regimens. We performed a retrospective analysis assessing the use ddAC KN522 impact sequencing before or after carboplatin/paclitaxel (CbT) pembrolizumab on multiple outcomes. 128 patients with TNBC...
Abstract The majority of human breast cancers are dependent on hormone-stimulated estrogen receptor alpha (ER) and sensitive to its inhibition. Treatment resistance arises in most advanced due genetic alterations that promote ligand independent activation ER itself or target genes. Whereas re-targeting the binding domain (LBD) with newer antagonists can work some cases, these drugs largely ineffective many backgrounds including fusions lose LBD hyperactivate targets. By identifying mechanism...
1085 Background: Sacituzumab govitecan (SG) and trastuzumab deruxtecan (TDXd) are antibody drug conjugates (ADCs) that approved for the treatment of HER2 low metastatic breast cancer (MBC). Both carry payloads which inhibit topoisomerase 1, it is unknown whether these ADCs retain clinical activity when used sequentially to each other. Here we present a retrospective study patients treated with both SG TDXd at our institution report real world progression free survival (PFS), factors...
Neuroimmunology and Neuroinflammation is an open access journal, with focuses on neuroimmunology neuroinflammation research, coverage extending to other basic clinical studies related neuroscience.
Background Progressive, metastatic non–small cell lung cancer (NSCLC) often requires the initiation of new systemic therapy. However, in patients with NSCLC that is oligoprogressive (≤3 lesions), local radiotherapy (RT) may allow for eradication resistant microclones and, therefore, continuation otherwise effective Methods Patients treated from 2008 to 2019 definitive doses RT all sites intracranial or extracranial oligoprogression without a change therapy were identified. Radiographic...
After disease progression on endocrine therapy (ET) plus a CDK4/6 inhibitor, there is no standardized sequence for subsequent treatment lines estrogen receptor positive (ER+) metastatic breast cancer (MBC). CDK4/6i retrial as strategy commonplace in modern clinical practice; however, the available prospective data investigating this have had inconclusive results. To frame real-world context, we performed retrospective analysis assessing efficacy of CDK4/6is 195 patients who previous exposure...
BackgroundPatients with stage IV oligometastatic (≤ 3 sites) non–small-cell lung cancer have a progression-free survival (PFS) and overall benefit when all sites of metastatic disease the primary tumor are treated radically consolidative radiotherapy (cRT). However, optimal selection patients most likely from cRT is yet to be defined.Patients MethodsPatients definitive (2008-2019) were retrospectively identified. Univariable Cox proportional-hazards model was used compare outcomes...
Abstract Background Unplanned hospitalization during cancer treatment is costly, can disrupt treatment, and affect patient quality of life. However, incidence risks factors for lung radiotherapy are not well characterized. Methods Patients treated with definitive intent radiation (≥45 Gy) between 2008 2018 at a tertiary academic institution were identified. In addition to patient, tumor, related characteristics, specific baseline frailty markers (Charlson comorbidity index, ECOG, reported...
Programmed cell death ligand 1 (PD-L1) is surface glycoprotein that regulates the cellular immune response and serves as a targetable checkpoint molecule. Previous studies have demonstrated consistent expression of PD-L1 by Reed-Sternberg (RS) cells, well nonmalignant tumor-infiltrating macrophages in classic Hodgkin lymphoma (CHL). Bone marrow involvement CHL uncommon, being present 5% to 10% cases, but indicates Ann Arbor stage IV disease. Given mixed inflammatory infiltrate characterizes...
After disease progression on endocrine therapy (ET) plus a CDK4/6 inhibitor, there is no standardized sequence for subsequent treatment lines estrogen receptor positive (ER+) metastatic breast cancer (MBC). CDK4/6i retrial as strategy commonplace in modern clinical practice; however, the available prospective data investigating this have had inconclusive results. To frame real-world context, we performed retrospective analysis assessing efficacy of CDK4/6is 195 patients who previous exposure...
Abstract Background: Standard of care systemic treatment for early stage triple negative breast cancer (TNBC) consists neoadjuvant chemoimmunotherapy based upon the results KEYNOTE 522 (KN-522). The KN522 regimen utilized q3week dosing doxorubicin plus cyclophosphamide (AC); however, dose-dense AC (ddAC) has shown superior OS compared to in anthracycline and taxane-based regimens (per CALGB 9741 EBCTCG analyses). We now present a retrospective study patients treated with ddAC modified KN-522...
1078 Background: Pembrolizumab has received tumor-agnostic approval for the treatment of unresectable/metastatic solid tumors carrying a tumor mutational burden (TMB) >10 mut/Mb. The registrational KEYNOTE-158 study, however, did not include any patients with metastatic breast cancer (MBC). Here we present retrospective study TMB-high MBC treated immune checkpoint inhibition (ICI) and report real-world efficacy endpoints, including progression free survival as well clinical genomic...
11522 Background: SHP2 is an oncogenic tyrosine phosphatase that transduces receptor kinase signaling in the RAS/MAPK pathway via phosphatase-mediated regulation of guanine nucleotide exchange factors. has recently been identified as a genetic dependency for chordoma, rare tumor type with no approved therapies (1), and preclinical studies inhibitors have demonstrated activity chordoma models. Methods: As part FLAGSHP-1 study, patients (pts) advanced or metastatic were enrolled either...
Abstract Simultaneous presentation of two separate primary breast cancers differing histology at initial diagnosis is an uncommon phenomenon; it even rarer to find these pathologically distinct populations within the same biopsy. Here we report case a patient diagnosed with clearly demarcated, heterogenous triple negative cancer (TNBC) and HER2+ that was treated hybrid chemoimmunotherapy regimen combining elements Keynote-522 standard HER2-directed neoadjuvant regimen, yielding apathologic...
Abstract Background: Unplanned hospitalization during cancer treatment is costly, can disrupt treatment, and affect patient quality of life. However, incidence risks factors for lung radiotherapy are not well characterized. Methods: Patients treated with definitive intent radiation (≥45 Gy) between 2008 2018 at a tertiary academic institution were identified. In addition to patient, tumor, related characteristics, specific baseline frailty markers (Charlson comorbidity index, ECOG, reported...
Introduction: Solid pseudopapillary neoplasm is an uncommon pancreatic with low malignant potential that occurs predominantly in young women. Incidence males or the pediatric population unusual; presentation as acute pancreatitis atypical. Case Report: A 12-year-old boy no past medical history presented to emergency department four months of progressive epigastric abdominal pain and nausea. Initial evaluation showed elevated lipase 758 units/liter, normal complete blood count full metabolic...
The Bethesda System for Reporting Thyroid Cytopathology (BSRTC) was introduced by the National Cancer Institute of Health in 2007 to provide guidelines on evaluating and diagnosing thyroid cytolopathology unify diagnostic terminology. BSRTC consists 6 categories which consist unsatisfactory, benign, atypia undetermined significance (AUS), follicular neoplasm (FN), suspicious malignancy (SM), malignant. purpose …